ClinicalTrials.gg
RecruitingNCT06134687Updated Mar 24, 2026

Novel Rigidizing Overtube in Colonic Endoscopic Submucosal Dissection

An interventional study of Endoscopic Submucosal Dissection and Novel Rigidizing Overtube in Gastrointestinal Neoplasm, sponsored by Baylor College of Medicine. Recruiting at 2 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Baylor College of Medicine · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 316 studies in Gastrointestinal Neoplasms with a site in United States — 83 open to participants now, 116 under way, 4 of them phase 3. Gastrointestinal Neoplasms · United States.

Planned enrollment
117th of 245
66 · median 60
Started
2024
with 21 others
No phase
96 of 316
26 open now
Primary completion
2026-12
later than 26 of 113 live
Registered
259th of 316
by date
Lead sponsor
9 of 316
Baylor College of Medicine

Among the 316 studies in Gastrointestinal Neoplasms with a site in United States, this one is the 117th largest by planned enrollment of the 245 interventional ones that give a count, is one of 22 that started in 2024, is one of 96 with no phase, reaches primary completion later than 26 of the 113 other live ones, and was the 259th registered.

Gastrointestinal Neoplasms

698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.

Browse Gastrointestinal Neoplasms studies →

Open to participants now

83 of the 316 studies in Gastrointestinal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 316 studies in Gastrointestinal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this prospective, single centre, 1:1, Post Market, randomized controlled, Investigator Initiated trial, is to compare the feasibility, safety efficacy, and clinical outcomes of colonic endoscopic submucosal dissection (ESD) utilizing a novel rigidizing overtube called Pathfinder® Endoscope Overtube (Neptune Medical, Burlingame California, USA) device in comparison to conventional ESD.

The research team hypothesize that with utilizing a novel rigidizing overtube the procedure time including dissection speed and closure time will be faster due to higher scope stability and greater control over the scope tip. Subsequently, the investigators anticipate lower immediate or delayed adverse events.

Read the detailed description

Endoscopic submucosal dissection (ESD) is preferred resection method for advanced colonic polyp due to its higher rates of en bloc and R0 resection which lead to higher curative resection rate.1 In comparison to gastric ESD, colonic ESD is more challenging due to colonic unique anatomy and configuration. Tumor of size ≥ 50 mm, spreading across ≥ two folds, flexure locations have been described as strong predictors for difficulties during colonic ESD.2 Redundant colon and looping during colonoscopy may preclude successful advancement of the colonoscope and maintaining stable position for complex polyp removal.

Historically, various methods have been applied to facilitate colonoscopy and scope advancement in challenging positions and redundant colonic loops such as application of external pressure, exchange to pediatric colonoscope, torque-based reduction maneuvers, and patient repositioning. However, despite these, scope tip stabilization could potentially remain as a challenging and limiting factor for procedure progress and could lead to a longer procedure time, sedation time and perhaps lower procedure success rate. In comparison overtube-assisted colonoscopy allows for straightening of the colon to decrease angulation and loop formation.3 Several variations of overtubes have been put to use in the last few decades with comparable results such as single-balloon and double-balloon enteroscope, spiral overtube-assisted colonoscopy and double-balloon platform (DiLumenTM). DiLumen system consists of a plastic sheet fitting layer with two balloon few inches from each other in the tip of the device facilitating the scope tip stability. Most recently the efficacy of DiLumen platform were evaluated in a multicenter study including 162 patients who underwent endoscopic resection of advanced polyps.4 In this study technical success was achieved in 92% of patients without any device related adverse event. 4 In this study using an overtube resulted in faster and more efficient dissection.4 In a retrospective study of 88 polyps located within the proximal colon, ESD with assistance of traditional single balloon overtube resulted in significantly less perforation rate in polyps ≥ 40mm in the proximal colon, despite overall similar en bloc and R0 resection rates comparison to conventional ESD.5 Most recently, a novel dynamic rigidizing overtube (Pathfinder, Neptune Medical, Burlingame, Calif, USA) has been introduced to face the challenges encountered during difficult colonoscopies and to ensure scope stabilization during endoscopic mucosal resection (EMR) and ESD. The overtube material is soft and pliable on flexible state, however when the vacuum is applied the entire tube becomes 15 times stiffer.6 This unique feature of the device provides scope flexibility during colonoscope introduction and entire device stability when rigidizing system is applied.

Our team collected preliminary prospective data of 58 polyps removed by EMR (24.1%) and ESD (75.9% ) with the assistance off rigidizing overtube. Technical success (ability to complete the entire resection using the device) and clinical success (ability of endoscopic removal of polyps without changing the initial resection intent) was achieved 100% and 90% of the time, respectively. On endoscopist feedback, the rigidizing overtube was though to assist in resection in 98.3% of polyps, although the polyp was located in a somewhat/very difficult location 81% of the time. For polyps in difficult locations, the rigidizing overtube was able to maintain scope position without falling back even once, 55% of the time. This result was presented at the most recent Digestive Disease Week conference in Chicago 2023 (p1932).

As this device has been put to use recently in the United States, published literature to demonstrate its safety and efficacy in colonic ESD is lacking. The main aim of this study is to compare the feasibility, safety efficacy, and clinical outcomes of colonic endoscopic submucosal dissection (ESD) utilizing a novel rigidizing overtube called Pathfinder® Endoscope Overtube (Neptune Medical, Burlingame CA, USA) device in comparison to conventional ESD.

03

Conditions studied

  • Gastrointestinal Neoplasm

Keywords

  • Endoscopic Submucosal Dissection
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is ≥ 22 years old.
  • Patients can provide written .
  • Patient is referred for ESD procedure of colonic neoplastic lesions and with one of the following criteria:

A - Lesions with prior resection or with scar at any size proximal to the sigmoid colon.

B - Granular lateral spreading tumors (GLST) more than 30mm. C - Non granular lateral spreading tumors (NGLST) more than 20 mm. D - Any suspected submucosal invasion such as Paris classification II a +II or lesions with positive non lifting sign.

Exclusion criteria

Exclusion Criteria:

  • Patient refused and/or unable to provide written .
  • Patient is a pregnant or nursing woman.
  • Lesions with morphology: pedunculated type (Paris Ip, Ips).
  • Lesions located within the sigmoid colon or rectum.
  • Lesions involving appendiceal orifice or ileocecal valve
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Treatment arm

    Will have endoscopic submucosal dissection performed with the use of the Pathfinder Endoscope Overtube.

    Procedure: Endoscopic Submucosal Dissection · Device: Novel Rigidizing Overtube

  • Active comparator
    Control arm

    Will have endoscopic submucosal dissection performed through conventional means (i.e. without the Pathfinder Endoscope Overtube).

    Procedure: Endoscopic Submucosal Dissection

Interventions

  • ProcedureEndoscopic Submucosal Dissection

    Removal of study eligible lesions per endoscopic submucosal dissection

    Also known as: ESD, Endoscopic resection

  • DeviceNovel Rigidizing Overtube

    Utilization of the Novel Rigidizing Overtube (Pathfinder) to aid in performing colonic endoscopic submucosal dissection

06

What researchers measure

Primary outcomes

  1. Total Procedure Time

    Total Procedure Time to perform ESD from scope in to scope out

    Time frame: Day 1 (procedure day)

Secondary outcomes

  1. Navigation Time

    Total time needed to reach the lesion

    Time frame: Day 1 (procedure day)

  2. Technical Success

    The ability to complete the entire resection using the device without the need to change to a different tool. This will be marked as either 'yes' or 'no' on the collection report form following the procedure by the research team.

    Time frame: Day 1 (procedure day)

  3. Clinical Success

    The ability of endoscopic removal of polyps without changing the initial resection intent. This will be marked as either 'yes' or 'no' on the collection report form following the procedure by the research team.

    Time frame: Day 1 (procedure day)

  4. En-bloc, R0, and curative resection rates

    As collected and measured for each group

    Time frame: Day 1 (procedure day)

  5. Dissection speed during colonic ESD as calculated by

    cm\^2/hr

    Time frame: Day 1 (procedure day)

  6. Closure time

    Time needed to close area following endoscopic resection

    Time frame: Day 1 (procedure day)

  7. Sedation time

    Total time patient spent under anesthesia

    Time frame: Day 1 (procedure day)

  8. User-feedback post-procedure

    Subjective assessment of the degree of difficulty reaching the lesion based on a brief questionnaire given to the endoscopist following the procedure.

    Time frame: Day 1 (procedure day)

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

Of 154 non-industry interventional studies with no phase under Gastrointestinal Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 30 months is below that.

Counting every sponsor, half of 164 studies reached it within 36 months; a quarter within 17 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2023
First posted
Nov 18, 2023
StartActual
Jun 4, 2024
Primary completionEst.
Dec 4, 2026
CompletionEst.
May 30, 2027
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06134687
Collaborators
Neptune Medical, Inc.
Responsible party
Mohamed Othman, MD (Principal Investigator, Baylor College of Medicine) — Principal investigator
First posted
Nov 18, 2023
Start date
Jun 4, 2024
Primary completion
Dec 4, 2026 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Mar 24, 2026

Study contacts

Michael Mercado, BS
Contact
Michael.Mercado@bcm.edu
713-798-3606
Sara Al Yasin, BS
Contact
Sara.AlYasin@bcm.edu
713-798-2308
Mohamed Othman, MD
principal investigator · Baylor College of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion